Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases. Its pipeline is built around protein kinase regulation, including programs aimed at conditions where existing treatments leave significant unmet need. The company focuses on research and development rather than marketed commercial products at present.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.8 | — | -15.4 | — |
| Q3 2025 | 3.3 | — | -14.6 | — |
| Q4 2025 | 1.3 | — | -19.8 | — |
| Q1 2026 | 2 | — | -19.8 | — |
| Q2 2026 | 1.6 | -8.3% | -21.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: NVE Corporation (NVEC), B&R Technology Merger Corp. (BRTM), MasterCraft Boat Holdings, Inc. (MCFT), Aquestive Therapeutics, Inc. (AQST), Crane Harbor Acquisition Corp. II (CRAN), AngioDynamics, Inc. (ANGO)